Dr. Moein Moghimi

Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine at the School of Pharmacy, and Translational and Clinical Research Institute, Newcastle University (UK), and an Adjoint Professor at the Skaggs School of Pharmacy, University of Colorado, Denver. He is co-founder of S M Discovery Group Inc. and S M Discovery Group Ltd. He further serves as an Associate Editor of Molecular Therapy (the flagship journal of the American Society of Gene Therapy) and Drug Delivery (Taylor and Francis). Previously, he was Chair of Nanomedicine at Durham University (UK), Professor of Nanomedicine at Copenhagen University, Director of the Centre for Pharmaceutical Nanotechnology and Nanotoxicology (Copenhagen University), Visiting Professor at the University of Padova (Italy) and Affiliate Professor at Houston Methodist Research Institute (Texas). He graduated with Honors in Biochemistry from the University of Manchester (UK) in 1985 and completed his PhD in Biochemistry at Charing Cross and Westminster Medical School (Imperial College). He is widely published and reported in the press, and recognised for his contribution to fundamental and translational research in nanomedicine and drug delivery, especially in mechanistic understanding of nanoparticle-mediated adverse reactions and complement activation processes, and as an inventor of many tissue-specific drug delivery systems and therapeutic platforms (e.g., NanoLigand Carriers for crossing the blood-brain barrier and targeting neurons and microglial cells). A 2021 study conducted by Stanford University list Moghimi among the top 0.1% of world’s leading scientists across in all fields, and top 60 in pharmacology in the world.